OneMedNet Corporation expands its iRWD™ Network, achieving 90 million patient journeys and 2,300 healthcare partner sites.
Quiver AI Summary
OneMedNet Corporation has announced that its OneMedNet iRWD™ Network has reached significant milestones, surpassing 90 million patient journeys and 270 million studies, with its healthcare partner network growing to over 2,300 sites. This achievement supports the strategic goals set forth to shareholders at the end of 2025, emphasizing the company’s commitment to expanding its data network as a key component of long-term value creation. CEO Aaron Green highlighted that the growth of the network enables OneMedNet to provide diverse and interconnected datasets crucial for life sciences, drug developers, and AI innovators. The company continues to enhance its offerings, including rare diseases and various diagnostic modalities, while also exploring applications beyond healthcare through its AI-driven data anonymization capabilities.
Potential Positives
- OneMedNet's iRWD™ Network has surpassed 90 million patient journeys and 270 million studies, demonstrating significant growth in data availability.
- The provider network has expanded by over 30% in less than a year, increasing from approximately 1,750 to more than 2,300 healthcare partner sites, enhancing collaboration opportunities.
- The company is addressing increasing demand for Real-World Data and AI foundational models, positioning itself favorably in the evolving healthcare landscape.
- OneMedNet's unique offerings, including specialized data coverage and proprietary AI capabilities, may significantly contribute to advancements in drug development and healthcare innovation.
Potential Negatives
- Forward-looking statements indicate potential risks and uncertainties regarding the company's ability to achieve its strategic goals and adapt to changing market conditions, which could negatively impact investor confidence.
- The emphasis on increasing the breadth and depth of data networks may suggest previous limitations in data coverage or quality that the company is now addressing.
- The mention of the volatile nature of Digital Assets and the associated risks could be a concern for investors regarding the company's investment strategy and financial stability.
FAQ
What is the OneMedNet iRWD™ Network?
The OneMedNet iRWD™ Network is a platform providing regulatory decision-grade, AI-Driven Real-World Data for healthcare insights.
How many patient journeys has OneMedNet recorded?
OneMedNet has surpassed 90 million patient journeys in its data network, reflecting significant growth in real-world data.
What areas of healthcare does OneMedNet focus on?
OneMedNet specializes in hard-to-find data covering rare diseases, oncology, cardiology, and various diagnostic modalities.
How many healthcare partner sites are in the network?
OneMedNet's network includes more than 2,300 healthcare partner sites, representing a significant increase over the last year.
What types of industries benefit from OneMedNet's data?
Beyond healthcare, OneMedNet's AI-anonymized data benefits industries like finance, retail, and telecom for secure data sharing and innovation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ONMD Insider Trading Activity
$ONMD insiders have traded $ONMD stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ONMD stock by insiders over the last 6 months:
- THOMAS KOSASA has made 3 purchases buying 1,144,953 shares for an estimated $999,998 and 0 sales.
- JEFFREY YU (Chief Medical Officer) purchased 903,614 shares for an estimated $749,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ONMD Hedge Fund Activity
We have seen 12 institutional investors add shares of $ONMD stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EXENCIAL WEALTH ADVISORS, LLC added 4,732,698 shares (+129.8%) to their portfolio in Q1 2026, for an estimated $4,023,266
- CORRECT CAPITAL WEALTH MANAGEMENT removed 4,504,955 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $4,955,450
- VANGUARD GROUP INC added 319,067 shares (+32.5%) to their portfolio in Q4 2025, for an estimated $350,973
- CITIGROUP INC added 135,445 shares (+inf%) to their portfolio in Q1 2026, for an estimated $115,141
- DISCOVERY CAPITAL MANAGEMENT, LLC / CT added 112,252 shares (+inf%) to their portfolio in Q1 2026, for an estimated $95,425
- UBS GROUP AG removed 97,500 shares (-85.7%) from their portfolio in Q1 2026, for an estimated $82,884
- VIRTU FINANCIAL LLC removed 43,438 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $36,926
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2,300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation. Today's announcement reflects the team's disciplined execution against that commitment – extending the breadth, depth, and connectivity of the network to meet accelerating demand for Real-World Data and AI foundational models.
Key Milestones:
- More than 90 million patient journeys, a 12.5% increase since April 2026 in just two months , with 270 million studies available.
- Expanded provider network by more than 30% in less than a year, growing from approximately 1,750 to more than 2,300 healthcare partner sites.
- Encompasses hard to find data such as rare diseases, oncology, cardiology, and beyond.
- Increased specialized multi-modal data coverage across Radiology, Cardiology, EEG, ECG, and other diagnostic modalities, alongside de-identified electronic health records.
“Surpassing 90 million patient journeys, 270 million studies, and 2,300 healthcare partner sites is exactly the kind of progress we told our shareholders to expect when we outlined our strategy at the end of 2025," said Aaron Green, President & CEO of OneMedNet. "Growing the network is a deliberate, central pillar of how we build durable value, and this milestone shows the team executing against that plan. Life sciences organizations, drug developers, and AI innovators increasingly require deeper, more diverse, and longitudinally connected datasets. By continuously expanding our provider partnerships and the breadth of our curated, multi-modal data, we are uniquely positioned to meet the needs of life sciences organizations, drug developers, and AI innovators — delivering durable, long-term value for our customers and shareholders."
About OneMedNet Corporation
OneMedNet is revolutionizing how the world unlocks Real-World Data (RWD), harnessing the untapped potential of over 2,130 healthcare sites through its iRWD™ platform. This isn’t just data—it’s the lifeblood of innovation, from de-identified medical imaging to electronic health records, fueling breakthroughs for drugmakers, medical device pioneers, and AI visionaries. With a network spanning rare diseases, oncology, cardiology, and beyond, OneMedNet delivers precision insights that redefine patient care and power the next wave of healthcare disruption.
Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking endless possibilities—rigorously testing production system upgrades, de-risking complex projects, and securely sharing sensitive data by stripping out personal information.
Learn more at www.onemednet.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the achievement of our strategies, , and statements generally about our products, plans and strategies.
Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; risks inherent with investing in Digital Assets, including Digital Asset’s volatility; our ability to implement our Digital Asset treasury strategy and its effects on our business; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
OneMedNet Contacts:
Michael Wong, VP Marketing
Email: [email protected]
SOURCE: ONEMEDNET CORPORATION